Want to see TSE:ADK full AI Analyst Report?
Diagnos (ADK) AI Stock Analysis
Top Page
Diagnos
(TSXV:ADK)
The score is primarily constrained by severe losses, declining revenue, and sustained cash burn. Mixed technical signals and the absence of meaningful valuation support provide only limited offset, producing a high-risk overall profile.
Diagnos (ADK) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 40.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 266.85K
- Price to Earnings (P/E)
- -8.1
- Beta (1Y)
- 0.52
- Revenue Growth
- -36.92%
- EPS Growth
- 13.03%
- Country
- Canada
- Employees
- 16
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Diagnos Business Overview & Revenue Model
Company Description
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations foc...
How the Company Makes Money
null
Diagnos Financial Statement Overview
Summary
Financial performance is severely weak: revenue has declined sharply, operating and net losses exceed $4 million, cash burn is persistently negative, and equity remains thin despite reduced debt and a return to positive shareholders’ equity.
Income Statement
18Very NegativeBalance Sheet
32NegativeCash Flow
15Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.48K | 65.48K | 103.80K | 438.83K | 267.07K | 331.52K |
| Gross Profit | -119.45K | -119.45K | -943.56K | -418.30K | -347.53K | -473.45K |
| EBITDA | -4.09M | -4.13M | -3.56M | -2.10M | -2.45M | -1.91M |
| Net Income | -4.56M | -4.56M | -4.29M | -2.61M | -2.05M | -3.38M |
Balance Sheet | ||||||
| Total Assets | 2.39M | 2.39M | 3.64M | 1.54M | 1.95M | 2.43M |
| Cash, Cash Equivalents and Short-Term Investments | 1.93M | 1.93M | 3.24M | 920.91K | 1.36M | 1.87M |
| Total Debt | 1.40M | 1.40M | 3.07M | 1.19M | 471.68K | 337.55K |
| Total Liabilities | 1.70M | 1.70M | 3.40M | 1.66M | 818.19K | 614.78K |
| Stockholders Equity | 686.90K | 686.90K | 233.11K | -113.51K | 1.13M | 1.82M |
Cash Flow | ||||||
| Free Cash Flow | -3.87M | -4.01M | -3.65M | -2.07M | -1.40M | -2.66M |
| Operating Cash Flow | -3.86M | -4.00M | -3.64M | -2.04M | -1.36M | -2.64M |
| Investing Cash Flow | 1.56M | 1.56M | -3.11M | 503.52K | 262.93K | -759.98K |
| Financing Cash Flow | 2.51M | 2.66M | 6.62M | 1.60M | 882.82K | 3.83M |
Diagnos Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Negative. The current price of 0.34 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.44, and above the 200-day MA of 0.31, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 27.26 is Positive, neither overbought nor oversold. The STOCH value of 14.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ADK.
Diagnos Peers Comparison
Overall Rating
TSE:AIDR44Neutral
TSE:CHS41Neutral
TSE:UDOC41Neutral- TSE:ADK41Neutral
TSE:DMED39Underperform
TSE:NARA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TSE:AIDR | 44Neutral | CAD 44.56M | -1.64 | -444.52% | ― | 415.06% | -54.80% |
| TSE:CHS | 41Neutral | CAD 10.29M | -1.76 | 64.52% | ― | 7.63% | -106.03% |
| TSE:UDOC | 41Neutral | CAD 5.18M | -1.59 | 355.56% | ― | 614.03% | 51.97% |
| TSE:ADK | 41Neutral | CAD 40.34M | -8.11 | 9999.00% | ― | -36.92% | 13.03% |
| TSE:DMED | 39Underperform | CAD 3.95M | -1.94 | 739.84% | ― | ― | -28.35% |
| TSE:NARA | 38Underperform | CAD 2.39M | -0.82 | 184.91% | ― | ― | 43.30% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:ADK | Diagnos Inc | 0.34 | -0.01 | -1.47% | |
| TSE:AIDR | Rocket Doctor Ai Inc | 0.44 | -0.44 | -50.00% | |
| TSE:CHS | Comprehensive Healthcare Systems Inc | 0.35 | -0.27 | -42.74% | |
| TSE:UDOC | Unidoc Health Corp. | 0.06 | -0.13 | -68.42% | |
| TSE:NARA | PanGenomic Health, Inc. Class A | 0.17 | -1.03 | -85.83% | |
| TSE:DMED | DiagnaMed Holdings Corp. | 0.03 | -0.06 | -66.67% |
Diagnos Corporate Events
Diagnos accelerates Canadian rollout of AI-driven CARA eye diagnostic system
PositiveDiagnos has begun nationwide deployment of its newly licensed CARA System in Canada following Health Canada’s marketing authorization for the AI-powered retinal imaging platform. The company has onboarded 28 optometry locations in two weeks, br...
Diagnos Seeks U.S. FDA Clarity on AI-Powered CARA Eye Screening System
PositiveDiagnos has submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration regarding the classification and regulatory requirements of its CARA System, following an earlier FDA pre-submission and responding to a specific...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026